TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04070313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.
Study: NCT02532361

Intervention type: DEVICE
Intervention: Hysteroscopic device placement including Essure (ESS305, BAY1454032)
Description: Essure is a permanent, minimally invasive, non-hormonal implantable device used for contraception and Adiana sterilization method is a combination of controlled thermal damage to the lining of the fallopian tube followed by insertion of a non-absorbable biocompatible silicone elastomer matrix within the tubal lumen
Study: NCT00396370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG strain Danish
Description: Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 2-8 X 10\^5 colony-forming units (CFU) intradermal in 100 microliters diluent.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG strain Danish
Description: Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 2-8 X 10\^5 colony-forming units (CFU) intradermal in 100 microliters diluent.
Study: NCT03284749

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal maternity pads
Description: Normal maternity pads
Study: NCT02100579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 10 ml of 0.25% bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preservative free normal saline
Description: 10 ml of preservative free normal saline
Study: NCT02666885

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Integration of PET/MRI in radiotherapy
Description: Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
Study: NCT01440452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Cycling
Description: You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
Study: NCT02532361

Intervention type: PROCEDURE
Intervention: Tubal ligation
Description: Tubal ligation or tubectomy is a surgical procedure for sterilization in which a woman's fallopian tubes are clamped and blocked, or severed and sealed, either method of which prevents eggs from reaching the uterus for implantation
Study: NCT01440452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Cycling
Description: You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Cycling
Description: You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling without FES
Description: You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
Study: NCT02117869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low furanocoumarin hybrid grapefruit juice
Description: 3 consecutive daily doses of 200ml low furanocoumarin grapefruit juice plus midazolam 5mg orally on the third day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular grapefruit juice
Description: 3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.

Intervention type: OTHER
Group type: OTHER
Intervention: Water (control)
Description: 3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
Study: NCT01833065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 10 mg/day
Description: Elobixibat 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 5 mg/day
Description: Elobixibat 5 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01834235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-1C
Description: NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.
Study: NCT00353145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (Gemox)
Description: 1000 mg/m\^2, infused at 10 mg/m\^2/min on Day 1 repeated every 14 days (one cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100 mg/m\^2 by vein infused on Day 2 over two hours, repeated every 14 days (one cycle).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Quality of Life Surveys
Study: NCT04293783

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L.Reuteri
Description: daily supplementation with two tablet for six months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily supplementation with two tablet for six months
Study: NCT01928511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleos(t)ide analogue therapy
Study: NCT04596579

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 Antibody Analysis
Description: 10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 Antibody Analysis
Description: 10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 Antibody Analysis
Description: 10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 Antibody Analysis
Description: 10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Weck-cel Swab Collection
Description: A Weck-cel swab will be used to collect secretions from the mucosal epithelium
Study: NCT02151695

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: panretinal photocoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept intravitreal injections
Study: NCT01300611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127 300 mcg/kg/day
Description: Injection, 300 mcg/kg/day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127 1000 mcg/kg/day
Description: Injection, 1000 mcg/kg/day for 28 days
Study: NCT04264819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTH258/Brolucizumab
Description: Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by Treat-to-Control regimen up to Week 44/46.
Study: NCT03002480

Intervention type: OTHER
Group type: OTHER
Intervention: Thromboelastography-Guided Treatment Regimen
Description: The thromboelastograph (TEG) will be used to determine the best bypassing agent for the management of subjects with severe hemophilia A with inhibitors. Patients will be assigned that bypassing agent and dose for the treatment of their bleeding episodes and subsequently will be followed for a period of 6 months to determine their annual bleeding rate.
Study: NCT02822482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
Study: NCT02998541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP640
Description: Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PVP-I 0.6%
Description: Participants will receive one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive one drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
Study: NCT02149394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice popsicle
Description: Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The experimental group received an ice popsicle made of 10 mL mineral water.~The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice were supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water at room temperature
Description: Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
Study: NCT03944161

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutrition supplement
Description: Hypercaloric and high protein supplement
Study: NCT04596579

Intervention type: DIAGNOSTIC_TEST
Intervention: Weck-cel Swab Collection
Description: A Weck-cel swab will be used to collect secretions from the mucosal epithelium
Study: NCT03944161

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional advice
Description: Advice given by the clinician
Study: NCT00396370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG strain Danish
Description: Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 2-8 X 10\^5 colony-forming units (CFU) intradermal in 100 microliters diluent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.1 mL of sterile Sauton medium for intradermal administration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.1 mL of sterile Sauton medium for intradermal administration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.1 mL of sterile Sauton medium for intradermal administration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.1 mL of sterile Sauton medium for intradermal administration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 60 mL of sterile phosphate buffered saline (PBS) for oral administration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 60 mL of sterile phosphate buffered saline (PBS) for oral administration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 60 mL of sterile phosphate buffered saline (PBS) for oral administration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 60 mL of sterile phosphate buffered saline (PBS) for oral administration.
Study: NCT03708510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restorative materials- Filtek Silorane
Description: Filtek Silorane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restorative materials- Filtek Silorane
Description: Filtek Silorane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restorative materials-Kalore
Description: Kalore

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restorative materials-Kalore
Description: Kalore

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preparation-Er,Cr:YSGG Laser
Description: Er,Cr:YSGG Laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preparation-Er,Cr:YSGG Laser
Description: Er,Cr:YSGG Laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preparation- Diamond Bur
Description: Bur

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preparation- Diamond Bur
Description: Bur
Study: NCT02073201

Intervention type: OTHER
Intervention: High-functioning older adults
Description: Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).

Intervention type: OTHER
Intervention: Lower-functioning older adults
Description: Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).

Intervention type: OTHER
Intervention: Young adults
Description: Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
Study: NCT03511287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Breathing through a device that offers resistance during inspiration. In this study the POWERbreathe device was used (POWERbreathe® K3, HaB International Ltd, UK).
Study: NCT03944161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional advice
Description: Advice given by the clinician
Study: NCT04012931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Rilpivirine 25 mg tablets for the 25 mg daily dose, or tablets for or a weight-adjusted dose. Administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV Background Regimen
Description: The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine \[AZT\], abacavir \[ABC\], tenofovir alafenamide \[TAF\], or tenofovir disoproxil fumarate \[TDF\] in combination with emtricitabine \[FTC\] or lamivudine \[3TC\]), whichever are approved and marketed or considered local standard of care for children aged between 2 and \< 12 years in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir \[DTG\] or raltegravir) can also be administered in combination with RPV, as appropriate.
Study: NCT05657431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: essential oils (Ylang ylang oil)
Description: inhaler aromatherapy
Study: NCT03667859

Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal Tactile Imaging
Description: Vaginal elasticity measurements using the Vaginal Tactile Imaging system.

Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal Tactile Imaging
Description: Vaginal elasticity measurements using the Vaginal Tactile Imaging system.
Study: NCT05657431

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (saline solutions)
Description: placebo saline solutions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: essential oils (lemon oil)
Description: inhaler aromatherapy
Study: NCT02356315

Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging
Description: Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.

Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging
Description: Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.
Study: NCT04087304

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk Status Optimization
Description: Assessment of risk factors putting surgical candidates of total hip and knee arthroplasty at higher risk of complication, and promoting risk factor optimization, thereby decreasing associated risk.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk Status Optimization
Description: Assessment of risk factors putting surgical candidates of total hip and knee arthroplasty at higher risk of complication, and promoting risk factor optimization, thereby decreasing associated risk.
Study: NCT02068027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Gel 0.1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01704521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegInterferon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegInterferon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study: NCT04596579

Intervention type: DIAGNOSTIC_TEST
Intervention: Weck-cel Swab Collection
Description: A Weck-cel swab will be used to collect secretions from the mucosal epithelium

Intervention type: DIAGNOSTIC_TEST
Intervention: Weck-cel Swab Collection
Description: A Weck-cel swab will be used to collect secretions from the mucosal epithelium
Study: NCT01704521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Study: NCT01863420

Intervention type: RADIATION
Intervention: Bone Marrow-sparing Intensity-Modulated Radiotherapy
Description: Use Bone Marrow-sparing Intensity-Modulated Radiotherapy to limit the dose of active bone marrow in radiation fields. The BM regions on the T1-weighted images that showed a signal intensity equal to or slightly higher than that of muscle were contoured as active BM

Intervention type: RADIATION
Intervention: Bone Marrow-sparing Intensity-Modulated Radiotherapy
Description: Use Bone Marrow-sparing Intensity-Modulated Radiotherapy to limit the dose of active bone marrow in radiation fields. The BM regions on the T1-weighted images that showed a signal intensity equal to or slightly higher than that of muscle were contoured as active BM
Study: NCT00335478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is \>500 cells/mm\^3.
Study: NCT02173873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept drug
Description: intravitreal injection of ziv-ablicerpt in one eye of each patient with retinal disease and poor vision
Study: NCT01032174

Intervention type: DRUG
Intervention: Azithromycin SR
Description: Azithromycin SR, 2.0 g by mouth (PO) x 1

Intervention type: DRUG
Intervention: Amoxiclav 1000 mg
Description: Amoxiclav 1000 mg x twice daily, 10 days
Study: NCT01837407

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Composite Flap
Description: nerve transfer with the dorsal branch of the digital nerve
Study: NCT04550910

Intervention type: RADIATION
Group type: OTHER
Intervention: Hypofractionation Schedules for Breast Cancer patients after mastecomy
Description: Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation Schedules for Breast Cancer patients after mastecomy
Description: Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.